300653.SZ
正海生物
SZSE · Healthcare · C 制造业 · CN
CNY 14.78
−1.92%Year over year
Reported trailing growth
- Revenue
- -6.3%
- EBITDA
- —
- EBIT
- -44.6%
- EPS
- -42.1%
- Free cash flow
- -59.2%
- Operating cash flow
- -53.9%
Forward estimates
Based on analyst estimates
- Revenue
- +3.2%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -5.6%
- EBITDA
- -21.5%
- EBIT
- -25.1%
- Net income
- -23.7%
- EPS
- -28.9%
- Free cash flow
- -12.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026